Metformin interactions
Pro Research Analysisby 
Searched over 200M research papers for "metformin interactions"
Consensus Meter
Metformin Interactions: A Comprehensive Overview
Metformin and Gut Microbiome Interactions
Metformin, a widely used drug for type 2 diabetes (T2D), has been shown to significantly alter the gut microbiome. A study involving treatment-naive T2D patients demonstrated that metformin induces changes in the gut microbiota, which in turn contributes to its therapeutic effects. The altered microbiota from metformin-treated individuals improved glucose tolerance when transferred to germ-free mice, indicating a direct link between metformin's action and gut microbiota modulation.
Pharmacokinetic and Pharmacodynamic Interactions with Evogliptin
Metformin is often used in combination with other antidiabetic drugs, such as evogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Research has shown that while the combination of metformin and evogliptin (EVO + MET) does not result in significant pharmacokinetic interactions, it enhances the pharmacodynamic effects. Specifically, EVO + MET increases active glucagon-like peptide-1 levels and reduces glucose more effectively than either drug alone, suggesting a synergistic therapeutic benefit without major pharmacokinetic concerns.
Drug-Drug Interactions and Transporter Proteins
Metformin's pharmacokinetics are heavily influenced by drug transporter proteins, particularly Organic Cation Transporters (OCTs) and Multidrug and Toxin Extruders (MATEs). Inhibition of these transporters by other drugs can lead to increased plasma concentrations of metformin, raising the risk of Metformin-Associated Lactic Acidosis (MALA). Identifying drugs that inhibit OCTs and MATEs is crucial for predicting and managing potential drug interactions with metformin.
Metformin and Cimetidine Interaction
Cimetidine, a known inhibitor of OCT2 and MATE, significantly affects metformin's pharmacokinetics. Studies using physiologically based pharmacokinetic models have shown that cimetidine increases metformin exposure, particularly in individuals with renal impairment. This interaction underscores the importance of adjusting metformin dosages in patients with compromised kidney function to avoid adverse effects.
Metformin as a Substrate and Inhibitor of Thiamine Transporter
Metformin is also a substrate for the human thiamine transporter THTR-2 (SLC19A3). This transporter, highly expressed in the small intestine, facilitates the absorption and tissue distribution of metformin. Metformin and other drugs can inhibit THTR-2, potentially leading to drug-drug and drug-nutrient interactions. This interaction highlights the complex interplay between metformin and various transport mechanisms in the body.
Mechanisms of Action and Mitochondrial Interactions
The exact mechanisms of metformin's action are multifaceted and not fully understood. Metformin primarily reduces hepatic glucose production and has been shown to act through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. It also inhibits mitochondrial respiratory-chain complex 1, reducing reactive oxygen species production and protecting against oxidative stress-induced cell death. These mitochondrial interactions are central to metformin's antidiabetic and potential antineoplastic properties .
Conclusion
Metformin's interactions are diverse, involving alterations in the gut microbiome, complex pharmacokinetic and pharmacodynamic relationships with other drugs, and significant roles of transporter proteins and mitochondrial functions. Understanding these interactions is crucial for optimizing metformin therapy and managing potential adverse effects, particularly in patients with comorbid conditions or those on multiple medications.
Sources and full results
Most relevant research papers on this topic